StoneX Group Inc. Acquires 1,593 Shares of Bristol-Myers Squibb (NYSE:BMY)

StoneX Group Inc. increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 10.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,266 shares of the biopharmaceutical company’s stock after purchasing an additional 1,593 shares during the quarter. StoneX Group Inc.’s holdings in Bristol-Myers Squibb were worth $842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of BMY. Caxton Associates LP lifted its position in Bristol-Myers Squibb by 5.5% during the first quarter. Caxton Associates LP now owns 27,369 shares of the biopharmaceutical company’s stock valued at $1,484,000 after purchasing an additional 1,430 shares during the period. Kennedy Capital Management LLC bought a new position in shares of Bristol-Myers Squibb during the 1st quarter valued at $2,588,000. Dynasty Wealth Management LLC purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter worth $1,265,000. Ancora Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 9.8% in the first quarter. Ancora Advisors LLC now owns 40,938 shares of the biopharmaceutical company’s stock worth $2,220,000 after acquiring an additional 3,654 shares during the period. Finally, B. Riley Wealth Advisors Inc. increased its position in Bristol-Myers Squibb by 13.7% during the first quarter. B. Riley Wealth Advisors Inc. now owns 185,863 shares of the biopharmaceutical company’s stock valued at $10,787,000 after acquiring an additional 22,462 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY opened at $58.87 on Monday. The firm has a market cap of $119.40 billion, a price-to-earnings ratio of -16.40, a P/E/G ratio of 15.62 and a beta of 0.44. The firm has a fifty day moving average price of $53.66 and a 200 day moving average price of $47.77. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.08. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business had revenue of $11.89 billion during the quarter, compared to the consensus estimate of $11.26 billion. During the same quarter in the prior year, the firm earned $2.00 EPS. The business’s revenue was up 8.4% on a year-over-year basis. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.08%. The ex-dividend date of this dividend was Friday, October 4th. Bristol-Myers Squibb’s payout ratio is -66.85%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. TD Cowen boosted their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Morgan Stanley boosted their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. Jefferies Financial Group lifted their price target on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research note on Wednesday, August 28th. Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Finally, Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $54.07.

Insider Activity

In related news, EVP Samit Hirawat acquired 1,830 shares of the stock in a transaction dated Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, with a total value of $100,046.10. Following the purchase, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares in the company, valued at $654,091.20. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.